Compile Data Set for Download or QSAR
maximum 50k data
Found 61 of ic50 for UniProtKB: P63165
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621214(US20230303584, Compound 311)
Affinity DataIC50:  130nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621186(US20230303584, Compound 254)
Affinity DataIC50:  140nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621203(US20230303584, Compound 294)
Affinity DataIC50:  160nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621191(US20230303584, Compound 266)
Affinity DataIC50:  190nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621222(US20230303584, Compound 321)
Affinity DataIC50:  240nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621200(US20230303584, Compound 285)
Affinity DataIC50:  240nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621209(US20230303584, Compound 302)
Affinity DataIC50:  250nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621197(US20230303584, Compound 280)
Affinity DataIC50:  260nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621201(US20230303584, Compound 288)
Affinity DataIC50:  270nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621215(US20230303584, Compound 312)
Affinity DataIC50:  280nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621194(US20230303584, Compound 272)
Affinity DataIC50:  300nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621226(US20230303584, Compound 325)
Affinity DataIC50:  320nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621220(US20230303584, Compound 318)
Affinity DataIC50:  330nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621223(US20230303584, Compound 322)
Affinity DataIC50:  340nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621225(US20230303584, Compound 324)
Affinity DataIC50:  340nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621231(US20230303584, Compound 330)
Affinity DataIC50:  350nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621224(US20230303584, Compound 323)
Affinity DataIC50:  390nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621196(US20230303584, Compound 279)
Affinity DataIC50:  400nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621211(US20230303584, Compound 307)
Affinity DataIC50:  400nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621212(US20230303584, Compound 308)
Affinity DataIC50:  430nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621206(US20230303584, Compound 298)
Affinity DataIC50:  440nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621187(US20230303584, Compound 255)
Affinity DataIC50:  500nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621188(US20230303584, Compound 256)
Affinity DataIC50:  510nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621190(US20230303584, Compound 265)
Affinity DataIC50:  560nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621208(US20230303584, Compound 301)
Affinity DataIC50:  560nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621217(US20230303584, Compound 314)
Affinity DataIC50:  560nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621229(US20230303584, Compound 328)
Affinity DataIC50:  580nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621219(US20230303584, Compound 317)
Affinity DataIC50:  620nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621189(US20230303584, Compound 264)
Affinity DataIC50:  640nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621234(US20230303584, Compound 336)
Affinity DataIC50:  650nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621230(US20230303584, Compound 329)
Affinity DataIC50:  720nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621193(US20230303584, Compound 271)
Affinity DataIC50:  770nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621228(US20230303584, Compound 327)
Affinity DataIC50:  850nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621199(US20230303584, Compound 284)
Affinity DataIC50:  860nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621227(US20230303584, Compound 326)
Affinity DataIC50:  870nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621240(US20230303584, Compound 353)
Affinity DataIC50:  890nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621192(US20230303584, Compound 267)
Affinity DataIC50:  900nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621210(US20230303584, Compound 304)
Affinity DataIC50:  900nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621221(US20230303584, Compound 319)
Affinity DataIC50:  930nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621233(US20230303584, Compound 335)
Affinity DataIC50:  940nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621241(US20230303584, Compound 354)
Affinity DataIC50:  960nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621195(US20230303584, Compound 277)
Affinity DataIC50:  1.10E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621205(US20230303584, Compound 297)
Affinity DataIC50:  1.40E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621198(US20230303584, Compound 281)
Affinity DataIC50:  1.50E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621218(US20230303584, Compound 316)
Affinity DataIC50:  1.50E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621236(US20230303584, Compound 342)
Affinity DataIC50:  1.51E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621239(US20230303584, Compound 352)
Affinity DataIC50:  1.56E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621237(US20230303584, Compound 343)
Affinity DataIC50:  1.58E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621216(US20230303584, Compound 313)
Affinity DataIC50:  1.70E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSmall ubiquitin-related modifier 1(Homo sapiens (Human))
Suvalent Therapeutics

US Patent
LigandPNGBDBM621242(US20230303584, Compound 355)
Affinity DataIC50:  1.97E+3nMAssay Description:Assay buffer was prepared [50 mM HEPES, pH 7.5, 0.1% BSA and 10 mM MgCl2] as was the Stop Buffer [100 mM HEPES, pH 7.5, 0.05% Tween20, and 410 mM KF]...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 61 total ) | Next | Last >>
Jump to: